{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:24:46Z","timestamp":1770956686949,"version":"3.50.1"},"reference-count":71,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2020,1,2]]},"DOI":"10.1080\/13696998.2019.1638789","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T06:17:15Z","timestamp":1562048235000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom"],"prefix":"10.1080","volume":"23","author":[{"given":"Lefteris","family":"Floros","sequence":"first","affiliation":[{"name":"Covance Market Access, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer Al","family":"Taie","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Weidlich","sequence":"additional","affiliation":[{"name":"Covance Market Access, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rita Capparella","sequence":"additional","affiliation":[{"name":"Pfizer PIO, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihalina","family":"Georgallis","sequence":"additional","affiliation":[{"name":"Covance Market Access, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita Hor-Yun","family":"Sung","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"CIT0001","unstructured":"ema.europa.eu. [Internet] London: European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169890.pdf"},{"key":"CIT0002","unstructured":"European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169714.pdf"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.01978.x"},{"key":"CIT0004","first-page":"195","volume":"139","author":"Badiee P","year":"2014","journal-title":"Indian J Med Res"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1086\/318483"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12428"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1159\/000196477"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/jac\/dku506","volume":"70","author":"Ceesay MM","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01124"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.067108-0"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065110"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1086\/504490"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-316430"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3201\/eid2302.152042"},{"key":"CIT0018","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Nov 2017 [cited Feb 2018]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/559\/SPC\/Fungizone\u00b150mg\u00b1Powder\u00b1for\u00b1Sterile\u00b1Concentrate"},{"key":"CIT0019","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Jan 2017 [cited Feb 2018]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5407"},{"key":"CIT0020","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Jul 2016 [cited Feb 2018]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2226"},{"key":"CIT0021","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Aug 2017 [cited Feb 2018]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5914"},{"key":"CIT0022","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Apr 2017 [cited Dec 2017]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/1236"},{"key":"CIT0023","unstructured":"ec.europa.eu. [Internet] London: European Commission; 2005 [cited Feb 2018]. Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2005\/200503299473\/anx_9473_en.pdf"},{"key":"CIT0024","unstructured":"ema.europa.eu. [Internet] London: European Medicines Agency; 2015 [cited Mar 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002734\/WC500196128.pdf"},{"key":"CIT0025","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Mar 2015 [cited Feb 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lbl.pdf"},{"key":"CIT0026","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Oct 2008 [cited Mar 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050740s016lbl.pdf"},{"key":"CIT0027","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Feb 2005 [cited Mar 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/21227s015lbl.pdf"},{"key":"CIT0028","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Nov 2015 [cited Mar 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf"},{"key":"CIT0029","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Feb 2015 [cited Mar 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021266s038,021267s047,021630s028lbl.pdf"},{"key":"CIT0030","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Apr 2012 [cited Mar 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020083s048s049s050lbl.pdf"},{"key":"CIT0031","unstructured":"aidsinfo.nih.gov. [Internet] US: US Department of Health and Human Services; Dec 2017 [cited Mar 2018]. Available from: https:\/\/aidsinfo.nih.gov\/drugs\/6\/amphotericin-b\/115\/professional"},{"key":"CIT0032","unstructured":"aidsinfo.nih.gov. [Internet] US: US Department of Health and Human Services; Dec 2017 [cited Mar 2018]. Available from: https:\/\/aidsinfo.nih.gov\/drugs\/6\/amphotericin-b\/117\/professional"},{"key":"CIT0033","unstructured":"ema.europa.eu. [Internet] London: European Medicines Agency; Oct 2015 [cited Mar 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002734\/WC500196128.pdf"},{"key":"CIT0034","unstructured":"accessdata.fda.gov. [Internet] US: Food and Drug Administration; Mar 2015 [cited Jan 2019]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lbl.pdf"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"CIT0038","unstructured":"Ullmann AJ, Selleslag D, Heinz W, et\u00a0al. A comparison of the safety profiles of isavuconazole vs voriconazole in the Phase 3 SECURE study in patients with invasive mould infections. Poster EP018 presented at 25th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Congress, Copenhagen, Denmark, April 25\u201328, 2015."},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0443-1"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3683-2"},{"key":"CIT0042","volume-title":"The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: Economic evaluation of the phase III vital study and FungiScope matched case-control analysis, in Poster presented at: 43rd Annual Meeting of the European Society for Blood and Marrow","author":"Bagshaw E","year":"2017"},{"key":"CIT0043","volume-title":"The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis, in Poster presented at: 27th European Congress of Clinical Microbiology and I","author":"Bagshaw E","year":"2017"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0231"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2018-0119"},{"key":"CIT0046","unstructured":"digital.nhs.uk. [Internet] UK: NHS Digital; 2016\/2017 [cited Feb 2019]. Available from: https:\/\/files.digital.nhs.uk\/publication\/7\/d\/hosp-epis-stat-admi-diag-2016-17-tab.xlsx"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00850.x"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.3"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12324"},{"key":"CIT0050","unstructured":"nice.org.uk. [Internet] UK: National Institute for Health and Care Excellence; Apr 2013 [cited Jan 2019]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case#discounting"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1086\/590004"},{"key":"CIT0052","unstructured":"accessdata.fda.gov. [Internet] US: Center For Drug Evaluation And Research; July 2014 [cited Jan 2019]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207500Orig1207501Orig1s000MedR.pdf"},{"key":"CIT0053","unstructured":"ema.europa.eu. [Internet] London: European Medicines Agency; July 2015 [cited Feb 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002734\/WC500196130.pdf"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"},{"key":"CIT0055","unstructured":"assets.publishing.service.gov.uk. [Internet] UK: Department of Health; 2016 [cited Jan 2019]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/577083\/Reference_Costs_2015-16.pdf"},{"key":"CIT0056","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; July 2018 [cited Jan 2019]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5388\/smpc"},{"key":"CIT0057","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; Jul 2018 [cited Jan 2019]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3435\/smpc"},{"key":"CIT0058","first-page":"447","volume":"136","author":"Fluckiger U","year":"2006","journal-title":"Swiss Med Weekly"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1164175"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03908.x"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"CIT0062","unstructured":"Matched-case analysis of primary mucormycosis patients from isavuconazole study 9766-CL-0103\/WSA-CS-003 to patients from FungiScope registry database. 2014."},{"key":"CIT0063","unstructured":"medicines.org.uk. [Internet] Middlesex: emc; 2018 [cited Jan 2019]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1022\/smpc"},{"key":"CIT0064","unstructured":"medicinescomplete.com. [Internet] UK: Medicines Complete; 2019 [cited Jan 2019]. Available from: https:\/\/about.medicinescomplete.com\/#\/browse\/bnf"},{"key":"CIT0065","unstructured":"Curtis L, Burns A, [Internet] UK: PSSRU; 2017 [cited Jan 2019]. Available from: https:\/\/kar.kent.ac.uk\/65559\/40\/65559_rep_UCR-2017-v13finalKAR.pdf"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.620"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S102207"},{"key":"CIT0069","first-page":"218","volume":"58","author":"Townsend R","year":"2015","journal-title":"Mycoses"},{"key":"CIT0070","unstructured":"Weidlich D, Hicks M, Floros L, et\u00a0al. Estimating the budget and clinical impact of introducing isavuconazole for the treatment of patients with possible invasive aspergillosis in the United Kingdom. 2018, Poster presented at ISPOR Europe, 10\u201314 Nov, 2018."},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.284"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1638789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1638789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T17:20:12Z","timestamp":1663867212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2019.1638789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,2]]}},"alternative-id":["10.1080\/13696998.2019.1638789"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2019.1638789","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}